CNChaitali Nikam

Chaitali Nikam

*This is an algorithmically generated author record based on publicly available information.

Chaitali Nikam has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    1 to 1, 11,111 Covid sample testing; Decoding the testing matrix!

    by Chaitali Nikam, Caesar Sengupta, Kallathikumar K, Krishnakumar S, PraveenKumar Ganesan

    Almost 100 yrs. after the 1918 Spanish Flu Pandemic, world is witnessing “Covid-19”, another Pandemic of similar scale. Interesting, parallels are being drawn between these two pandemics –occurring a century apart; on their scale of spread, potential impact, global scare and attention, containment measures and even people are framing similar projections on possible course of the pandemic. While world was equally unprepared on many terms to safeguard itself from such a pandemic from SARS Cov-2 Virus, one scenario quite distinct from the previous pandemic scenario, is the current status of laboratories with advanced tools. Ground breaking genomic technologies such as NAAT (Nucleic acid Amplification technologies) or PCR (Polymerase Chain Reaction), which currently exist can be positioned as crucial weapons strategically for both community level operations and patient level care. We have the opportunity for cross learning from the experiences of the laboratories involved in Covid testing while informing our peers across policy, diagnostic and research domains, exciting the newcomers to join forces and educating all our associates who can be involved in supportive roles and the large numbers of innovators / supporters who can offer to improvise and strengthen on our current solutions.

  • Open Access

    Cytomegalovirus in Indian systemic lupus erythematosus patients: trouble maker or onlooker?

    by Shalini Dubey, Camilla Rodrigues, Chaitali Nikam, Rohini Samant

    INTRODUCTION: CMV infection has been reported to be associated with onset/exacerbation of SLE. In an attempt to verify this we studied CMV infection in SLE patients. METHODS: forty-two SLE patients were studied at 3-time points; disease onset/flare, at peak of immunosuppression (at 6 weeks) and at low doses of immunosuppression (at 6months). We studied healthy blood donors as controls, only once. Clinical assessment and SLE Disease Activity Index scoring was done at each visit. RT-PCR and ELISA were performed to detect CMV viral-load and anti-CMV antibodies (Ab) respectively. RESULTS: nine of 106 patients had detectable viral-load [145-50,000copies/ml]. Of these nine, three patients had significant viral-load, 6 patients had low viral-loads of doubtful clinical significance. None of the patients developed CMV disease. Six of 42 cases were positive for IgM Abs. All controls were negative for CMV DNA as well as CMV IgM Abs. All samples from patients and controls were positive for CMV IgG Ab indicating widespread prevalence. CONCLUSION: significantly, a higher seroprevalence of CMV IgM Abs against CMV observed in SLE patients when compared to controls, indicating possible reactivation due to immune modulation.


  • Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India?

    by Jai Bharat Mullerpattan, Chaitali Nikam, Ujjwal Sharma, Camilla Rodrigues, Lancelot Mark Pinto

    Time is tissue: an effective empiric regimen for multidrug-resistant TB tailored to local epidemiologyhttp://ow.ly/Tzw530c2uoI


  • Rifampicin (Rif)-resistant tuberculosis (TB) on GeneXpert in Mumbai, India: How effective is the best derived empiric regimen?

    by Jai Mullerpattan, Chaitali Nikam, Ujjwal Sharma, Radhika Banka, V. Pratibh Prasad, Camilla Rodrigues, Lancelot Pinto

    Background: Prevalence of multi drug resistant (MDR) TB in Mumbai is estimated to be as high as 24% among patients newly diagnosed with TB. Analysis of consecutive 238 Rif-resistant TB culture isolates at our institute in 2014 concluded that the five most effective drugs were second-line injectables, ethionamide, fluoroquinolones, para-amino salicylic acid (PAS) and clofazimine (Presented at ERS annual congress 2015). Aim: To validate the above 5-drug-regimen in a cohort of Rif-resistant isolates. Methods: From June to September 2015, 491 consecutive TB culture isolates were analysed and the adequacy of the above regimen was tested. An adequate regimen was one that met the WHO criteria of a minimum of 4 effective drugs. All drugs were weighted equally. Results: Of 491 isolates, 259(52%) were Rif-resistant. The derivation and validation cohorts had similar drug susceptibilities (Figure 1). ![Figure][1] A prescription with the above 5 drugs would result in 132(51%) patients being treated with at least 4 effective drugs, and 209(81%) being treated with a minimum of 3 effective drugs. Conclusion: Prescribing the 5 most susceptible drugs failed to provide an effective regimen for almost half of our cohort. In the absence of line probe assays, we recommend the addition of drugs such as cycloserine or linezolid (untested here) for empiric treatment, while awaiting results of cultures and susceptibility tests. [1]: pending:yes

  • Rapid diagnosis of childhood TB: Can we meet pediatric TB requirements?

    by Chaitali Nikam, Asawari Chavan, Swapna Naik, Archana Khillari, Lancelot Pinto, Anjali Shetty, Camilla Rodrigues

  • Open Access

    Multi-drug resistant tuberculous meningitis

    by Priti Kambli, Chaitali Nikam, Anjali Shetty, Rajeev Soman, Camilla Rodrigues


  • Open Access

    An Xpert screen to identify carbapenemases

    by Mubin Kazi, Chaitali Nikam, Anjali Shetty, Camilla Rodrigues


  • Open Access

    Redefining MTBDRplus test results: what do indeterminate results actually mean?

    by C. Nikam, R. Patel, M. Sadani, K. Ajbani, M. Kazi, R. Soman, A. Shetty, S. B. Georghiou, T. C. Rodwell, A. Catanzaro, et al.

    BACKGROUND: Although line-probe assays (LPAs) are promising, little research has been conducted to elucidate the true nature of indeterminate LPA results or assess the ability of these assays to perform on a wide range of clinical samples. OBJECTIVE: To evaluate the performance of the commercially available GenoType® MTBDRplus LPA against conventional BACTEC™ MGIT™ 960 culture and drug susceptibility testing (DST) among 308 pulmonary tuberculosis (PTB) and 32 extra-pulmonary TB samples. RESULTS: Invalid LPA results (defined as those with a missing Mycobacterium tuberculosis identification band) were obtained for 18 PTB samples, which were excluded from further analysis. The sensitivity and specificity of the MTBDRplus assay for multidrug-resistant TB, based upon the results obtained for the remaining 322 samples, was respectively 95.2% and 95.1%. Of 290 PTB samples, 40 (13.7%) were indeterminate on LPA (defined as the absence of both wild-type and corresponding mutation bands) for isoniazid (INH) and/or rifampicin (RMP), and were further evaluated by pyrosequencing (PSQ). Contrary to standard LPA interpretation, INH and RMP susceptibility were confirmed by both DST and PSQ in respectively 7.5% (3/40) and 27.5% (11/40) of indeterminate samples. CONCLUSION: PSQ was found to be a valuable and rapid technique to resolve discrepancies in LPA test results that were not interpretable.


  • Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures?

    by Ujjwal Sharma, Chaitali Nikam, Radhika Banka, Camilla Rodrigues, Lancelot Pinto

    Background: There is high prevalence of drug-resistant tuberculosis(TB) cases in Mumbai.Xpert MTB/RIF is a rapid and accurate point-of-care test for detecting MTB,and rifampicin(Rif) resistance.After diagnosis using Xpert MTB/RIF,phenotypic drug susceptibility testing(DST)results are available few weeks later.Patients have to be treated empirically with combinations of drugs,while awaiting DST reports. Aim: To determine prevalence of drug resistance to 12 other drugs tested,when MTB strain is Rif-resistant. Methods: Between June 2014-February 2015 consecutive 13-drug DSTs performed at microbiology laboratory at P.D.Hinduja Hospital, Mumbai were included.Prevalence of resistance to 12 drugs in presence of resistance to Rif was determined,and positive predictive value of Rif resistance in determining resistance to each of the other drugs was calculated. Results: Resistance to rifampicin was detected in 238 of 423 samples analyzed(56.3%).Results are summarized. Table 1 Discussion: In Indian setting,a combination of aminoglycoside,ethionamide,quinolone,PAS and Clofazimine would possibly be the best empiric treatment for rifampicin-resistant cases detected on Xpert MTB/RIF.


  • A study of CMV infection in SLE patients

    by Shalini Dubey, Camilla Rodrigues, Chaitali Nikam, Rohini Samant